Antisense Oligonucleotide Treatment for PCARP Disease Due to Mutation in FLVCR1
Antisense Oligonucleotide Treatment for PCARP Disease Due to Mutation in FLVCR1
Enrolling by invitation · NCT06565572 · Registry updated 2026-05-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Antisense Oligonucleotide Treatment for PCARP Disease Due to Mutation in FLVCR1 | posterior column ataxia-retinitis pigmentosa syndrome | Enrolling by invitation | Early phase 1 | 2026-05-19 | NCT06565572 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| University of Colorado, Denver | 475 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Childrens Hospital Colorado | Aurora | United States | 23 |